Positive Results from Fibrocell Science

Zacks

Fibrocell Science, Inc. (FCSC) recently announced encouraging data from a study named “Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status.” The study aimed at the conversion of research-grade adult skin cells into clinical grade induced pluripotent stem (iPS) cells.

The company has collaborated with UCLA Department of Molecular and Medical Pharmacology for the study.

Fibrocell Science was also in the news last month when the U.S. Patent and Trademark Office awarded a patent to the company related to its marketed product LAVIV. The patent protects LAVIV in the U.S. till 2031.

We note that LAVIV, an autologous cellular product, is approved for use in adults for improvement of the appearance of moderate-to-severe nasolabial fold wrinkles. For the second quarter of 2013, Fibrocell Science recorded revenues of less than $0.1 million for LAVIV.

The company is looking to expand the LAVIV label and assessing the product for several indications including the treatment of restrictive burn scars (RBS). In May 2013, the company announced the initiation of a phase II study (n = 21) evaluating LAVIV for the treatment of RBS.

The double-blind, randomized, placebo-controlled phase II study is enrolling patients with burn scars that restrict range of motion of jointed areas such as elbows, shoulders and fingers. The approval of LAVIV in this indication will provide RBS patients with an alternative to currently available standard treatment, surgery or laser.

Fibrocell Science currently carries a Zacks Rank #3 (Hold). Companies that look attractive at present include Actelion Ltd. (ALIOF) and Gilead Sciences Inc. (GILD) with a Zacks Rank #1 (Strong Buy), and Jazz Pharmaceuticals Public Limited Company (JAZZ) with a Zacks Rank #2 (Buy).

Read the Full Research Report on GILD

Read the Full Research Report on ALIOF

Read the Full Research Report on JAZZ

Read the Full Research Report on FCSC

Zacks Investment Research



More From Zacks.com
View Comments (0)